UY32711A - Nueva forma cristalina de pemirolast - Google Patents

Nueva forma cristalina de pemirolast

Info

Publication number
UY32711A
UY32711A UY0001032711A UY32711A UY32711A UY 32711 A UY32711 A UY 32711A UY 0001032711 A UY0001032711 A UY 0001032711A UY 32711 A UY32711 A UY 32711A UY 32711 A UY32711 A UY 32711A
Authority
UY
Uruguay
Prior art keywords
pemirolast
crystal form
new crystal
new
sodium salt
Prior art date
Application number
UY0001032711A
Other languages
English (en)
Spanish (es)
Inventor
Perlberg Anett
Viertelhaus Martin
Ulrika Rosenstroem
Horvath Karol
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of UY32711A publication Critical patent/UY32711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Dental Preparations (AREA)
UY0001032711A 2009-06-16 2010-06-15 Nueva forma cristalina de pemirolast UY32711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16

Publications (1)

Publication Number Publication Date
UY32711A true UY32711A (es) 2011-01-31

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032711A UY32711A (es) 2009-06-16 2010-06-15 Nueva forma cristalina de pemirolast

Country Status (31)

Country Link
US (3) US20120157415A1 (OSRAM)
EP (2) EP3141549A1 (OSRAM)
JP (2) JP5722317B2 (OSRAM)
KR (2) KR20170049645A (OSRAM)
CN (1) CN102596202B (OSRAM)
AR (1) AR077915A1 (OSRAM)
AU (1) AU2010261540B2 (OSRAM)
BR (1) BRPI1015559A2 (OSRAM)
CA (1) CA2765408A1 (OSRAM)
CY (1) CY1118413T1 (OSRAM)
DK (1) DK2443120T3 (OSRAM)
EA (1) EA025865B1 (OSRAM)
ES (1) ES2613059T3 (OSRAM)
HR (1) HRP20170023T1 (OSRAM)
HU (1) HUE032978T2 (OSRAM)
IL (1) IL216670A (OSRAM)
LT (1) LT2443120T (OSRAM)
ME (1) ME02685B (OSRAM)
MX (1) MX2011013676A (OSRAM)
NZ (1) NZ596747A (OSRAM)
PL (1) PL2443120T3 (OSRAM)
PT (1) PT2443120T (OSRAM)
RS (1) RS55558B1 (OSRAM)
SA (1) SA114350792B1 (OSRAM)
SG (1) SG176295A1 (OSRAM)
SI (1) SI2443120T1 (OSRAM)
SM (2) SMT201700085T1 (OSRAM)
TW (1) TWI504599B (OSRAM)
UY (1) UY32711A (OSRAM)
WO (2) WO2010146348A2 (OSRAM)
ZA (1) ZA201109045B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510837A (ja) * 2009-11-13 2013-03-28 カルドズ・アーベー 全身性軽度炎症の新しい処置
AU2013381855B2 (en) * 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
JP6596697B2 (ja) * 2016-10-03 2019-10-30 ブリベンションファーマシューティカル(シャンハイ)インコーポレイテッド Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド[1,2―a]ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
US8686189B2 (en) 2005-09-16 2014-04-01 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
ES2394984T3 (es) 2006-12-18 2013-02-07 Cardoz Ab Nueva combinación para uso en el tratamiento de trastornos inflamatorios
AU2007336077A1 (en) 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
JP2012530118A (ja) 2012-11-29
BRPI1015559A2 (pt) 2016-04-26
EA201200017A1 (ru) 2013-10-30
US20120157415A1 (en) 2012-06-21
MX2011013676A (es) 2012-02-08
US20140329839A1 (en) 2014-11-06
AU2010261540B2 (en) 2016-04-14
CY1118413T1 (el) 2017-06-28
CA2765408A1 (en) 2010-12-23
TWI504599B (zh) 2015-10-21
SMT201700085B (it) 2017-03-08
WO2010146348A2 (en) 2010-12-23
IL216670A0 (en) 2012-02-29
JP5722317B2 (ja) 2015-05-20
PL2443120T3 (pl) 2017-04-28
WO2010146341A3 (en) 2011-03-03
ME02685B (me) 2017-06-20
WO2010146348A9 (en) 2012-05-03
CN102596202A (zh) 2012-07-18
WO2010146348A3 (en) 2011-03-03
WO2010146341A2 (en) 2010-12-23
HRP20170023T1 (hr) 2017-03-10
SMT201700085T1 (it) 2017-03-08
ZA201109045B (en) 2013-05-29
EP3141549A1 (en) 2017-03-15
KR20120032530A (ko) 2012-04-05
IL216670A (en) 2017-02-28
AU2010261540A2 (en) 2012-01-19
LT2443120T (lt) 2017-02-10
ES2613059T3 (es) 2017-05-22
DK2443120T3 (en) 2017-01-09
AR077915A1 (es) 2011-10-05
US20170202839A1 (en) 2017-07-20
HUE032978T2 (hu) 2017-11-28
EA025865B1 (ru) 2017-02-28
SG176295A1 (en) 2012-01-30
PT2443120T (pt) 2017-02-08
SI2443120T1 (sl) 2017-04-26
SA114350792B1 (ar) 2015-11-10
CN102596202B (zh) 2015-01-21
NZ596747A (en) 2014-01-31
TW201100422A (en) 2011-01-01
KR20170049645A (ko) 2017-05-10
US9006431B2 (en) 2015-04-14
EP2443120B1 (en) 2016-11-02
EP2443120A2 (en) 2012-04-25
AU2010261540A1 (en) 2012-01-19
JP2015120750A (ja) 2015-07-02
RS55558B1 (sr) 2017-05-31

Similar Documents

Publication Publication Date Title
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
ECSP11011444A (es) Inhibidores del canal de potasio medular externo renal
CR20130369A (es) Novedosos derivados heterocíclicos
PL3512252T3 (pl) Schematy przekazywania komunikatów o awarii
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
EA201590321A1 (ru) Дейтерированный барицитиниб
BRPI1010795A2 (pt) compostos antivirais
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
CR20110432A (es) Pirimidinas fusionadas
PT2623498E (pt) Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida
DOP2010000053A (es) Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno
CR20130539A (es) Triazolopiridinas
CR20130419A (es) Derivados heterocíclicos de amina
FIC20260012I1 (fi) Molidustaatti, erityisesti molidustaattinatrium
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
EP2423203A4 (en) CRYSTAL OF A BENZOXAZINONE COMPOUND
CY1118413T1 (el) Κρυσταλλικη μορφη πεμιρολαστης
CL2009001973S1 (es) Mostrador.
CR20110275A (es) 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina
CR20120169A (es) Procesos para la preparación de 2-(1-feniletil)-isoindolin-1-ona
MX2014002454A (es) Nueva forma de cristal.
CL2010000016S1 (es) Seccion de una llave ciega.
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190207